<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613570</url>
  </required_header>
  <id_info>
    <org_study_id>SUPREME</org_study_id>
    <nct_id>NCT04613570</nct_id>
  </id_info>
  <brief_title>SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up</brief_title>
  <acronym>SUPREME</acronym>
  <official_title>SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Portugues de Oncologia, Francisco Gentil, Porto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Portugues de Oncologia, Francisco Gentil, Porto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Gastric atrophy and intestinal metaplasia are the principal precursors for&#xD;
      gastric cancer and, therefore, are considered gastric premalignant conditions. Although&#xD;
      current guidelines recommend surveillance of individuals with these conditions, the best&#xD;
      method for its identification and staging (histological vs endoscopy) and the best time&#xD;
      schedule for follow-up are still controversial. Aims: To describe for the first-time patients&#xD;
      with premalignant conditions both clinically (familial history), histologically (OLGA/OLGIM;&#xD;
      complete/incomplete metaplasia) and endoscopically (EGGIM) using validated scales and to&#xD;
      describe evolution of these parameters through time. To estimate prospectively the gastric&#xD;
      cancer risk according to EGGIM stages. To define the best endoscopic surveillance follow-up&#xD;
      for the several stages considering clinical, histological and endoscopic factors.&#xD;
&#xD;
      Methods: Multicenter study involving different gastroenterology departments from several&#xD;
      countries. Consecutive patients older than 45 years scheduled for upper endoscopy in each of&#xD;
      these centers will be evaluated by High-Resolution- endoscopy with virtual chromoendoscopy&#xD;
      and EGGIM will be calculated. Guided biopsies (if areas suspicious of IM) and/or random&#xD;
      biopsies (if no areas suspicious of IM) in antrum and corpus will be made and OLGA/OLGIM&#xD;
      stages calculated. Patients will be evaluated in clinical consultation and database will be&#xD;
      fulfilled. All patients will be eradicated for Helicobacter pylori infection if positive. At&#xD;
      that occasion, all the patients with EGGIM&gt;5 and/or OLGA III/IV and/or OLGIM III/IV will be&#xD;
      randomized for yearly (12 to 16 months) or every three years (32-40 months) endoscopic&#xD;
      follow-up during a period of 6 years (SUPREME I). Endoscopic observational follow-up will be&#xD;
      scheduled for patients with EGGIM 1-4 and OLGIM I/II at 3 and 6 years (SUPREME II). For&#xD;
      individuals with no evidence of IM (EGGIM 0 and OLGIM 0, OLGA 0-II) a follow-up endoscopy 6&#xD;
      years after will be proposed (SUPREME III).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: Gastric atrophy and intestinal metaplasia are the principal precursors for&#xD;
      gastric cancer and, therefore, are considered gastric premalignant conditions. Although&#xD;
      current guidelines recommend surveillance of individuals with these conditions, the best&#xD;
      method for its identification and staging (histological vs endoscopy) and the best time&#xD;
      schedule for follow-up are still controversial. Aims: To describe for the first-time patients&#xD;
      with premalignant conditions both clinically (familial history), histologically (OLGA/OLGIM;&#xD;
      complete/incomplete metaplasia) and endoscopically (EGGIM) using validated scales and to&#xD;
      describe evolution of these parameters through time. To estimate prospectively the gastric&#xD;
      cancer risk according to EGGIM stages. To define the best endoscopic surveillance follow-up&#xD;
      for the several stages considering clinical, histological and endoscopic factors.&#xD;
&#xD;
      Methods: Multicenter study involving different gastroenterology departments from several&#xD;
      countries. Consecutive patients older than 45 years scheduled for upper endoscopy in each of&#xD;
      these centers will be evaluated by High-Resolution-endoscopy with virtual chromoendoscopy and&#xD;
      EGGIM will be calculated. Guided biopsies (if areas suspicious of IM) and/or random biopsies&#xD;
      (if no areas suspicious of IM) in antrum and corpus will be made and OLGA/OLGIM stages&#xD;
      calculated. Patients will be evaluated in clinical consultation and database will be&#xD;
      fulfilled. All patients will be eradicated for Helicobacter pylori infection if positive. At&#xD;
      that occasion, all the patients with EGGIM&gt;5 and/or OLGA III/IV and/or OLGIM III/IV will be&#xD;
      randomized for yearly (12 to 16 months) or every three years (32-40 months) endoscopic&#xD;
      follow-up during a period of 6 years (SUPREME I). Endoscopic observational follow-up will be&#xD;
      scheduled for patients with EGGIM 1-4 and OLGIM I/II at 3 and 6 years (SUPREME II). For&#xD;
      individuals with no evidence of IM (EGGIM 0 and OLGIM 0, OLGA 0-II) a follow-up endoscopy 6&#xD;
      years after will be proposed (SUPREME III).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with EGGIM &gt; 5 or OLGA/OLGIM III/IV (premalignant stomach group - SUPREME I) will be randomized to endoscopic surveillance every one (12 to 16 months) or three years (32-40 months);</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dysplasia</measure>
    <time_frame>6 years</time_frame>
    <description>Proportion of patients with dysplasia (low or high-grade)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carcinoma</measure>
    <time_frame>6 years</time_frame>
    <description>Proportion of patients with gastric adenocarcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Curative criteria</measure>
    <time_frame>6 years</time_frame>
    <description>Proportion of patients with intramucosal carcinoma with low-risk criteria (&quot;curative&quot; criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-curative criteria</measure>
    <time_frame>6 years</time_frame>
    <description>Proportion of patients with submucosal, diffuse type or intramucosal carcinoma with high-risk criteria (&quot;non-curative&quot; criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Advanced gastric cancer</measure>
    <time_frame>6 years</time_frame>
    <description>Proportion of patients with advanced gastric cancer (without indication for endoscopic treatment)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">912</enrollment>
  <condition>Atrophic Gastritis</condition>
  <condition>Intestinal Metaplasia</condition>
  <condition>Gastric Dysplasia</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Yearly endoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upper gastrointestinal endoscopy every year (12-16 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endoscopy every 3 years</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Upper gastrointestinal endoscopy every three years (32-40 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Upper gastrointestinal endoscopy</intervention_name>
    <description>In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made;&#xD;
Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial;&#xD;
EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification:&#xD;
If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol;&#xD;
If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area;&#xD;
Antrum, incisura and corpus fragments should be sent in 3 separate vials;</description>
    <arm_group_label>Endoscopy every 3 years</arm_group_label>
    <arm_group_label>Yearly endoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for upper GI endoscopy with indication for gastric biopsies,&#xD;
             including those with known gastric pathology (e.g. auto-immune gastritis) or&#xD;
             premalignant conditions (e.g patients under surveillance because of atrophic&#xD;
             gastritis);&#xD;
&#xD;
          -  Age above 45 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of previous gastrectomy;&#xD;
&#xD;
          -  History of endoscopic resection of neoplastic lesion&#xD;
&#xD;
          -  History of previous gastric dysplasia (even with no detectable lesion)&#xD;
&#xD;
          -  Hereditary syndromes that increase gastric cancer risk (familial adenomatous&#xD;
             polyposis; Lynch syndrome)&#xD;
&#xD;
          -  Serious comorbidities (ASA 3 or more)&#xD;
&#xD;
          -  Medication with anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Pimentel-Nunes, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Português de Oncologia do Porto, Francisco Gentil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Pimentel-Nunes, MD PhD</last_name>
    <phone>+35122508400</phone>
    <phone_ext>3348</phone_ext>
    <email>pedro.nunes@ipoporto.min-saude.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diogo Libanio, MD PhD</last_name>
    <phone>+35122508400</phone>
    <phone_ext>7442</phone_ext>
    <email>diogo.monteiro@ipoporto.min-saude.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IPO-Porto</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diogo Libanio, MD PhD</last_name>
      <phone>+351910288892</phone>
      <email>diogo.monteiro@ipoporto.min-saude.pt</email>
    </contact>
    <contact_backup>
      <last_name>Pedro Nunes, MD PhD</last_name>
      <phone>+351967340096</phone>
      <email>pedro.nunes@ipoporto.min-saude.pt</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Portugues de Oncologia, Francisco Gentil, Porto</investigator_affiliation>
    <investigator_full_name>Diogo Libânio</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>atrophic gastritis</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>intestinal metaplasia</keyword>
  <keyword>gastric dysplasia</keyword>
  <keyword>surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastritis, Atrophic</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Metaplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT04613570/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

